X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (32) 32
humans (27) 27
oncology (26) 26
article (13) 13
male (12) 12
cancer (11) 11
gene amplification (11) 11
female (10) 10
adult (9) 9
aged (9) 9
c-met (9) 9
middle aged (9) 9
gastric cancer (8) 8
mutation (8) 8
tumors (8) 8
stomach neoplasms - genetics (7) 7
stomach neoplasms - pathology (7) 7
survival (7) 7
adenocarcinoma (6) 6
advanced gastric-cancer (6) 6
aged, 80 and over (6) 6
clinical trials (6) 6
double-blind (6) 6
expression (6) 6
gastric-cancer (6) 6
open-label (6) 6
stomach cancer (6) 6
treatment outcome (6) 6
amplification (5) 5
biomarkers (5) 5
breast-cancer (5) 5
cell lung-cancer (5) 5
disease-free survival (5) 5
esophageal neoplasms - genetics (5) 5
gastroesophageal adenocarcinoma (5) 5
growth-factor receptor (5) 5
her2 (5) 5
met (5) 5
neoplasms - genetics (5) 5
therapy (5) 5
adenocarcinoma - genetics (4) 4
chemotherapy (4) 4
esophageal cancer (4) 4
esophageal neoplasms - pathology (4) 4
growth factors (4) 4
hematology, oncology and palliative medicine (4) 4
heterogeneity (4) 4
immunohistochemistry (4) 4
kinases (4) 4
medical prognosis (4) 4
metastasis (4) 4
neoplasm staging (4) 4
neoplasms (4) 4
patients (4) 4
proteins (4) 4
proto-oncogene proteins c-met - genetics (4) 4
proto-oncogene proteins c-met - metabolism (4) 4
receptor, erbb-2 - metabolism (4) 4
stomach neoplasms - drug therapy (4) 4
stomach neoplasms - mortality (4) 4
abridged index medicus (3) 3
animals (3) 3
antineoplastic agents - therapeutic use (3) 3
biomarkers, tumor - genetics (3) 3
biomarkers, tumor - metabolism (3) 3
c-met protein (3) 3
cancer therapies (3) 3
care and treatment (3) 3
cell line, tumor (3) 3
cisplatin (3) 3
computer simulation (3) 3
egfr (3) 3
esophageal neoplasms - mortality (3) 3
gastrointestinal tumors (3) 3
gene (3) 3
gene expression (3) 3
growth (3) 3
hematology (3) 3
her2 gene amplification (3) 3
human activities (3) 3
in situ hybridization, fluorescence (3) 3
lapatinib (3) 3
mass spectrometry (3) 3
medical research (3) 3
medicine (3) 3
met protein (3) 3
molecular targeted therapy - methods (3) 3
multidisciplinary sciences (3) 3
mutations (3) 3
phase-ii trial (3) 3
precision medicine (3) 3
prognosis (3) 3
proteomics - methods (3) 3
proto-oncogene proteins c-met - antagonists & inhibitors (3) 3
receptor (3) 3
receptor, erbb-2 - genetics (3) 3
regulatory approval (3) 3
research article (3) 3
resistance (3) 3
signal transduction (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Molecular Oncology, ISSN 1574-7891, 05/2015, Volume 9, Issue 5, pp. 967 - 996
The promise of 'personalized cancer care' with therapies toward specific molecular aberrations has potential to improve outcomes. However, there is recognized... 
Gastroesophageal cancer | Expansion Platform Designs | Intra-patient heterogeneity | Inter-patient heterogeneity | Esophagogastric cancer | Next-generation clinical trials | PANGEA | Molecular heterogeneity | Gastric cancer | Esophagus cancer
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2019, Volume 37, Issue 15_suppl, pp. e18229 - e18229
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2019, Volume 37, Issue 15_suppl, pp. e13131 - e13131
Journal Article
Cancer discovery, ISSN 2159-8274, 02/2019, Volume 9, Issue 2, pp. 166 - 168
Sanchez-Vega and colleagues prospectively demonstrate that both intra-and intertumoral differential expression of the receptor tyrosine kinases HER2, EGFR, and... 
HETEROGENEITY | RESISTANCE | THERAPY | ONCOLOGY
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 08/2019, Volume 37, Issue 24, pp. 2177 - 2177
Journal Article
The Oncologist, ISSN 1083-7159, 11/2019, Volume 24, Issue 11, pp. 1462 - 1468
Background With the exception of trastuzumab, therapies directed at receptor tyrosine kinases (RTKs) in gastroesophageal adenocarcinomas (GEA) have had limited... 
Receptor tyrosine kinase | Heterogeneity | Gastric cancer | Fibroblast growth factor receptor 2 | Gastroesophageal junction adenocarcinoma
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2017, Volume 35, Issue 4_suppl, pp. 60 - 60
60 Background: Gastroesophageal cancer (GEC) is a global health problem. Multiple phase III anti-EGFR trials of unselected metastatic GEC patients (pts) were... 
Journal Article
The Oncologist, ISSN 1083-7159, 04/2019, Volume 24, Issue 4, pp. 475 - 482
Background The randomized phase III RAINBOW trial established paclitaxel (pac) plus ramucirumab (ram) as a global standard for second‐line (2L) therapy in... 
Second line | Ramucirumab | GEJ adenocarcinoma | Gastric cancer | FOLFIRI | MULTICENTER PHASE-II | JUNCTION CANCER | OPEN-LABEL | CHEMOTHERAPY | CAPECITABINE | HETEROGENEITY | CISPLATIN | ONCOLOGY | ADVANCED GASTRIC-CANCER | DOUBLE-BLIND | 1ST-LINE THERAPY | Index Medicus | Gastrointestinal Cancer
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2019, Volume 37, Issue 4_suppl, pp. 118 - 118
118 Background: Preclinical studies suggest that MMP9 inhibition relieves immune suppression and promotes T cell infiltration to potentiate checkpoint... 
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2019, Volume 37, Issue 4_suppl, pp. 91 - 91
91 Background: GC with FGFR2b overexpression or FGFR2 amplification is associated with a poor prognosis. Bemarituzumab (bema, FPA144) is a first-in-class... 
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2019, Volume 37, Issue 8_suppl, pp. 43 - 43
43 Background: PD-1 targeting with pembrolizumab or nivolumab leads to durable clinical benefits in patients (pts) with microsatellite instability-high (MSI-H)... 
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2019, Volume 37, Issue 4_suppl, pp. 75 - 75
75 Background: Andecaliximab (ADX) is a monoclonal antibody that inhibits matrix metalloproteinase 9 (MMP9). Preclinical studies suggest that MMP9 inhibition... 
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2019, Volume 37, Issue 4_suppl, pp. 65 - 65
65 Background: Trastuzumab (T) + chemo is standard first-line therapy (tx) for HER2+ gastroesophageal adenocarcinoma (GEA) pts, though progression ensues in... 
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2017, Volume 35, Issue 7_suppl, pp. 16 - 16
16 Background: Gastroesophageal adenocarcinoma (GEC) is a significant global health problem. KEYNOTE-012 demonstrated a 22% objective response rate in patients... 
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2018, Volume 36, Issue 4_suppl, pp. 45 - 45
45 Background: Esophagogastric junction (EGJ) and gastric (GC) cancer, together GEA, have a poor prognosis, high molecular heterogeneity, and few targeted... 
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2018, Volume 36, Issue 4_suppl, pp. 43 - 43
43 Background: The DDR pathway is important in tumor biology, allowing cancer cells a mechanism to resist damage by chemotherapy and radiotherapy. BRCA1/2 are... 
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.